OPUS TIMI 16

OBJECTIVE: To determine if an oral GP IIb/IIIa inhibitor, orbofiban, reduces major cardiovascular events for the treatment of patients with an unstable coronary syndrome within 72 hours.

View/Download
_______________________________________________________________________________

  1. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Brassard JA, Curtis BR, Cooper RA, et al. Thromb Haemost 2002;88:892-7.
    | Abstract | Request Reprints |

  2. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Am J Cardiol 2000;85:491-3, A10.
    | Abstract | Request Reprints |

  3. High-sensitivity C-reactive protein is a potent predictor of long term mortality in 3225 patients with acute coronary syndromes: Results from OPUS-TIMI 16. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Charlesworth A, Ridker PM, Anders R, Rifai N, Braunwald E. Circulation 2000;102(Suppl. II):II-499.
    | Request Reprints |

  4. Thrombocytopenia, bleeding, and thrombotic events with oral Glycoprotein IIb/IIIa inhibition: Results from OPUS-TIMI 16. Coulter SA, Cannon CP, Cooper RA, McCabe CH, Aster R, Charlesworth A, Skene AM, Braunwald E. J Am Coll Cardiol 2000;35(Suppl A):393A.
    | Request Reprints |

  5. Can long-term outcome in acute ischemic syndromes be reliably predicted by abnormal acute ECG and enzyme abnormalities? Kovar D, Rogers WJ, Cannon CP, Charlesworth A, Skene A, Caspi A, Langer A. J Am Coll Cardiol 2000;35(Suppl A):375 A.
    | Request Reprints |

  6. International differences in acute coronary syndrome outcomes are related to angiography rates. Langer A, Cannon CP, Goodman SG, Charlesworth A, Hill C, McCabe C, Braunwald E. J Am Coll Cardiol 2000;35(Suppl A):375A.
    | Request Reprints |

  7. Role of oral blockade of platelet Glycoprotein IIb/IIIa on neutrophil-platelet interactions in patients with acute coronary syndromes. Serrano CV, Venturinelli M, Ramires JAF, Cannon CP, Nicolau JC. J Am Coll Cardiol 2000;35(Suppl A):343A.
    | Request Reprints |

  8. Prior aspirin use is univariate, but not a multivariate predictor of 1 year mortality in 10,302 patients with acute coronary syndromes: Results from OPUS-TIMI 16. Sharis P, Cannon CP, McCabe CH, Charlesworth A. J Am Coll Cardiol 2000;35(Suppl.A):391A.
    | Request Reprints |

  9. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Am J Cardiol 2001;87:636-9, A10.
    | Abstract | Request Reprints |

  10. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. de Lemos JA, Morrow DA, Bentley JH, et al. N Engl J Med 2001;345:1014-21.
    | Abstract | Request Reprints |

  11. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Blood 2001;98:3256-60.
    | Abstract | Request Reprints |

  12. Are there high-risk patients who are troponin negative? Further risk stratification with the TIMI risk score in patients with acute coronary syndromes: results from OPUS-TIMI 16. Cannon CP, McCabe CH, Antman EM, Bentley J, Rifai N, Braunwald E. J Am Coll Cardiol 2001;37(Suppl A):326A.
    | Request Reprints |

  13. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16.Cannon CP, McCabe CH, Bentley J, Braunwald E. J Am Coll Cardiol 2001;37(Suppl. A):334A.
    | Request Reprints |

  14. Effect of beta-blockers on mortality in patients with acute coronary syndromes: OPUS-TIMI 16 substudy. Kovar D, Bentley JH, Charlesworth A, Rogers WJ. Circulation 2001(Suppl II):II-725.
    | Request Reprints |

  15. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Kovar D, Cannon CP, Bentley JH, Charlesworth A, Rogers WJ. Circulation 2001;104(Suppl II);II-727.
    | Request Reprints |

  16. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. J Thromb Thrombolysis 2002;13:13-9.
    | Abstract | Request Reprints |

  17. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Shields DC, Fitzgerald AP, O'Neill PA, et al. Pharmacogenomics J 2002;2:182-90.
    | Abstract | Request Reprints |

  18. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology.Brassard JA, Curtis BR, Cooper RA, et al. Thromb Haemost 2002;88:892-7.
    | Abstract | Request Reprints |

  19. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. J Thromb Thrombolysis 2002;13:13-9.
    | Abstract | Request Reprints |

  20. The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Shields DC, Fitzgerald AP, O'Neill PA, et al. Pharmacogenomics J 2002;2:182-90.
    | Abstract | Request Reprints |


  21. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.Cotter G, Cannon CP, McCabe CH, et al. Am Heart J 2003;145:622-7.
    | Abstract | Request Reprints |

  22. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. de Lemos JA, Morrow DA, Sabatine MS, et al. Circulation 2003;107:690-5.
    | Abstract | Request Reprints |


  23. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Morrow DA, Rifai N, Sabatine MS, et al. Clin Chem 2003;49:1396-8.
    | Abstract | Request Reprints |

  24. Soluble CD40L: risk prediction after acute coronary syndromes. Varo N, de Lemos JA, Libby P, et al. Circulation 2003;108:1049-52.
    | Abstract | Request Reprints |

  25. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes. Serrano CV, Jr., Nicolau JC, Venturinelli M, et al. Cardiovasc Drugs Ther 2003;17:129-32.
    | Abstract | Request Reprints |

  26. Association between blood glucose and long term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 Trial.Bhadriraju S, Cannon CP, DeFranco AC, Barber K, Bhadriraju P, Gibson CM, Morrow D, McCabe C, Braunwald E. Circulation 2003;108:1475.
    | Request Reprints |

  27. Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18. Wylie JV, Murphy SA, Morrow DA, de Lemos JA, Antman EM, Cannon CP. Am Heart J 2004;148:173-80.
    | Abstract | Request Reprints |

  28. Higher levels of thrombus precursor protein are associated with increased death and ischemic complications in patients with acute coronary syndromes. Mega J, Sabatine MS, Morrow D, de Lemos J, Murphy S, McCabe C, Cannon CP, Braunwald E. J Am Coll Cardiol 2004;43:306A.
    | Request Reprints |

  29. Treatment and outcomes of eastern Europeans with coronary syndromes in OPUS-TIMI 16. Gurjeva OS, Bukhman G, Murphy S, Cannon CP. Int J Cardiol 2005;100:101-7.
    | Abstract | Request Reprints |

  30. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. Cantor WJ, Goodman SG, Cannon CP, et al. Am Heart J 2005;149:275-83.
    | Abstract | Request Reprints |

  31. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial.Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Am Heart J 2005;149:444-50.
    | Abstract | Request Reprints |

  32. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. Kirtane AJ, Leder DM, Waikar SS, et al. J Am Coll Cardiol 2005;45:1781-6.
    | Abstract | Request Reprints |

  33. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Bhadriraju S, Ray KK, DeFranco AC, et al. Am J Cardiol 2006;97:1573-7.
    | Abstract | Request Reprints |

  34. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. O'Donoghue M, de Lemos JA, Morrow DA, et al. Circulation 2006;114:550-7.
    | Abstract | Request Reprints |

  35. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. Scirica BM, Cannon CP, Cooper R, et al. J Thromb Thrombolysis 2006;22:95-102.
    | Abstract | Request Reprints |

  36. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Am Heart J 2006;151:976 e1-6.
    | Abstract | Request Reprints |

  37. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes--Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Am Heart J 2006;151:338-44.
    | Abstract | Request Reprints |

  38. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. Scirica BM, Cannon CP, Cooper R, et al. J Thromb Thrombolysis 2006;22:95-102.
    | Abstract | Request Reprints |

  39. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. Olenchock BA, Wiviott SD, Murphy SA, et al. J Thromb Thrombolysis 2008;26:79-84.
    | Abstract | Request Reprints |

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group